Enliven Therapeutics Inc. (ELVN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Enliven Therapeutics Inc. (ELVN) has a cash flow conversion efficiency ratio of -0.021x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.53 Million) by net assets ($895.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Enliven Therapeutics Inc. for the company's overall valuation and market capitalisation.
Enliven Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Enliven Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Enliven Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Enliven Therapeutics Inc. ranked by their cash flow conversion efficiency. See ELVN operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PTT OIL+RET.BUS.-NVDR- 10
F:7F80
|
-0.360x |
|
Brady Corporation
NYSE:BRC
|
0.058x |
|
Asbury Automotive Group Inc
NYSE:ABG
|
0.057x |
|
Yangtze Optical Electronic Co. Ltd. A
SHG:688143
|
N/A |
|
Liechtensteinische Landesbank Aktiengesellschaft
F:LLS1
|
-0.060x |
|
Dolby Laboratories
NYSE:DLB
|
0.134x |
|
Scorpio Tankers Inc.
F:S0QA
|
0.048x |
|
Shaanxi Sirui Advanced Materials Co. Ltd. A
SHG:688102
|
N/A |
Annual Cash Flow Conversion Efficiency for Enliven Therapeutics Inc. (2017–2025)
The table below shows the annual cash flow conversion efficiency of Enliven Therapeutics Inc. from 2017 to 2025. View Enliven Therapeutics Inc. stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $459.49 Million | $-70.30 Million | -0.153x | +35.23% |
| 2024-12-31 | $309.85 Million | $-73.19 Million | -0.236x | +5.19% |
| 2023-12-31 | $245.91 Million | $-61.27 Million | -0.249x | -159.67% |
| 2022-12-31 | $-76.83 Million | $-32.08 Million | 0.418x | +333.19% |
| 2021-12-31 | $106.86 Million | $-19.13 Million | -0.179x | -77.26% |
| 2020-12-31 | $84.44 Million | $-8.53 Million | -0.101x | +86.65% |
| 2019-12-31 | $28.92 Million | $-21.88 Million | -0.757x | +49.38% |
| 2018-12-31 | $5.87 Million | $-8.78 Million | -1.494x | -48.63% |
| 2017-12-31 | $8.74 Million | $-8.79 Million | -1.005x | -- |
About Enliven Therapeutics Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversibl… Read more